HIV vaccines may 'harm' patients

HIV vaccines being developed may do patients more harm than good, studies in mice suggest.

The latest findings strengthen concerns that the adenoviruses being used in some experimental HIV vaccines could speed up T-cell exhaustion.

This would mean a HIV-positive patient would progress more rapidly to AIDS.

Recombinant adeno-associated viruses (rAAV) have been used as vectors to carry selected elements of the HIV-1 virus and act as a vaccine. The latest research could explain why clinical trials into such vaccines have so far led to disappointing results.

It focused on rAAV vectors of different serotypes, all of which expressed HIV-1 gag proteins - essential for virus replication.

The vaccines were injected into female mice, which received a primer and a booster injection one to two months later.

Follow-up assays on immune response demonstrated that CD8+ T cells produced in response to the vaccine poorly protected from infection in a challenge model.

They also proliferated poorly when they came into contact with their antigen.

Additionally, only low levels of the cytokine interferon-gamma were produced in response to gag stimulation.

If an rAAV-vector vaccine against HIV dampens immune response in this way, it could increase the recipient's susceptibility to AIDS by removing their natural immune defences, say the study authors.

Lead researcher Dr Hildegund Ertl, from the Wistar Institute Vaccine Center in Philadelphia, said: 'The results mean that rAAV vaccines against HIV may cause harm and that, without additional preclinical studies, they should not be used in humans.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Vaccination tracker

UK COVID-19 vaccination programme tracker

GPs across the UK have led the largest-ever NHS vaccination programme in response...

RCGP chair Professor Martin Marshall

Hand PCNs control of primary care infrastructure funding, says RCGP

CCG funding for primary care infrastructure should be handed to PCNs when the bodies...

Professor Martin Marshall and Talking General Practice logo

Podcast: RCGP chair Professor Martin Marshall

Talking General Practice speaks to RCGP chair Professor Martin Marshall.

Dr Chaand Nagpaul

In-house review not enough to stop 'unjust' GMC referrals, warns BMA

Doctors' leaders have repeated calls for a full independent review of the GMC referral...

Coronavirus

How widespread is long COVID in the UK?

Millions of people in the UK are living with long COVID. GPonline looks at the data...

COVID-19 vaccination sign

GP contract for autumn COVID-19 booster campaign due shortly

GP practices in England will be invited shortly to sign up for the COVID-19 autumn...